Literature DB >> 23625215

Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus.

Jae Il Yoo1, Jung Wook Kim, Gi Su Kang, Hwa Su Kim, Jung Sik Yoo, Yeong Seon Lee.   

Abstract

Vancomycin intermediate Staphylococcus aureus (VISA) strains are increasingly prevalent in the hospital setting, and are of major concern in the treatment of methicillin-resistant S. aureus infections. Multiple mutations in vancomycin-susceptible S. aureus (VSSA) strains likely led to the emergence of VISA, and point mutations in the agr, orf1, yvqF, vraSR, graSR, and tcaRAB genes of VISA strains have been shown to contribute to glycopeptide resistance. Therefore, we investigated point mutations in these genes from 87 VISA and 27 VSSA clinical strains isolated from Korean hospitals. All strains were assigned an agr type (I, II, or III) on the basis of multiplex PCR, with the majority of VISA strains belonging to agr groups I and II. Sequencing revealed amino acid changes in vraS from VISA strains which were not present in the VSSA strains. The E59D substitution in the vraR gene occurred in 36.3% of VSSA/agrI and 92.7% of VISA/agrI strains, suggesting that this mutation associated with emergence of VISA/agrI strains. VISA strains were classified into 31 mutation patterns according to mutations in the yvqF, vraSR, graSR, and tcaRAB genes. In addition, the mutation patterns were correlated with agr and sequence type (ST). The most prevalent pattern included agr type I (ST 72) strains with E59D (vraR), L26F and T224I (graS), D148Q (graR), and L218P, R283H and G312D (tcaA) amino acid substitutions. The minimum inhibitory concentration (MIC) range of mutation pattern 5 toward oxacillin and imipenem was much lower than that of patterns 6 and 24. These results improve our understanding of emergence of VISA strains.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23625215     DOI: 10.1007/s12275-013-3088-7

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  23 in total

1.  Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006.

Authors:  Gyungtae Chung; Jeongok Cha; Sunyoung Han; Heesun Jang; Kyeongmin Lee; Jaeil Yoo; Jeongsik Yoo; Hongbin Kim; Soohoon Eun; Bongsu Kim; Ok Park; Yeong seon Lee
Journal:  J Microbiol Biotechnol       Date:  2010-03       Impact factor: 2.351

Review 2.  The management of infections due to drug-resistant gram-positive bacteria.

Authors:  R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

3.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

4.  Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis.

Authors:  Philippe Gilot; Gérard Lina; Thierry Cochard; Bernard Poutrel
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

5.  Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Christine Wennersten; Lata Venkataraman; Richard P Novick; Howard S Gold
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR.

Authors:  Yoshihisa Kato; Takahisa Suzuki; Takashi Ida; Kazunori Maebashi
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790

Review 7.  New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community.

Authors:  Keiichi Hiramatsu; Keiko Okuma; Xiao Xue Ma; Munetaka Yamamoto; Satoshi Hori; Maria Kapi
Journal:  Curr Opin Infect Dis       Date:  2002-08       Impact factor: 4.915

8.  Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus.

Authors:  Adriana Renzoni; William L Kelley; Christine Barras; Antoinette Monod; Elzbieta Huggler; Patrice François; Jacques Schrenzel; René Studer; Pierre Vaudaux; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

9.  Impact of sigB mutation on Staphylococcus aureus oxacillin and vancomycin resistance varies with parental background and method of assessment.

Authors:  Vineet K Singh; Jennifer L Schmidt; R K Jayaswal; Brian J Wilkinson
Journal:  Int J Antimicrob Agents       Date:  2003-03       Impact factor: 5.283

10.  Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus.

Authors:  Andrea Jansen; Michael Türck; Christiane Szekat; Michael Nagel; Indra Clever; Gabriele Bierbaum
Journal:  Int J Med Microbiol       Date:  2007-04-05       Impact factor: 3.473

View more
  8 in total

1.  Genome Sequence of a Highly Virulent pvl-positive Vancomycin-intermediate-resistant Staphylococcus aureus Sequence Type 30.

Authors:  Raiane C Chamon; Lucas M Marques; Jorge Timenetsky; Caio T C da Costa Rachid; Rosana B R Ferreira; Tamara L R de Oliveira; Thais Glatthardt; Lilian de Oliveira Moreira; Kátia R N Dos Santos
Journal:  Curr Genomics       Date:  2020-02       Impact factor: 2.236

2.  Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.

Authors:  Bruk Mensa; Gabriella L Howell; Richard Scott; William F DeGrado
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

Review 3.  Targeting cell membrane adaptation as a novel antimicrobial strategy.

Authors:  Truc T Tran; William R Miller; Yousif Shamoo; Cesar A Arias
Journal:  Curr Opin Microbiol       Date:  2016-07-25       Impact factor: 7.934

4.  Genome sequence-based discriminator for vancomycin-intermediate Staphylococcus aureus.

Authors:  Lavanya Rishishwar; Robert A Petit; Colleen S Kraft; I King Jordan
Journal:  J Bacteriol       Date:  2013-12-20       Impact factor: 3.490

5.  Novel single-nucleotide variations associated with vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.

Authors:  Lee-Chung Lin; Shih-Cheng Chang; Mao-Cheng Ge; Tsui-Ping Liu; Jang-Jih Lu
Journal:  Infect Drug Resist       Date:  2018-01-18       Impact factor: 4.003

Review 6.  Vancomycin Resistance in Staphylococcus aureus
.

Authors:  Will A McGuinness; Natalia Malachowa; Frank R DeLeo
Journal:  Yale J Biol Med       Date:  2017-06-23

7.  Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA).

Authors:  Michelle Su; Michelle H Davis; Jessica Peterson; Claudia Solis-Lemus; Sarah W Satola; Timothy D Read
Journal:  PeerJ       Date:  2021-07-13       Impact factor: 3.061

8.  Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.

Authors:  Yamuna Devi Bakthavatchalam; Priyanka Babu; Elakkiya Munusamy; Hariharan Triplicane Dwarakanathan; Priscilla Rupali; Marcus Zervos; Peter John Victor; Balaji Veeraraghavan
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.